RP-1664

CAT: 0804-HY-172737-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-172737-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of PLK4 and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research[1][2].
CAS Number
[2980682-00-4]
UNSPSC
12352211
Target
Polo-like Kinase (PLK)
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
98.77
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(NC2=NC(N(C3=C(C=C(C=C3F)S(C)(=O)=O)F)C)=NC(C4=CN(C=N4)C)=C2C5CC5)=NN1
Molecular Formula
C23H24F2N8O2S
Molecular Weight
514.55
References & Citations
[1]Isabel Soria-Bretones, et al. A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma. bioRxiv. February 17, 2025.|[2]Vallée F, et al. Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor. J Med Chem. 2025 Jun 12;68 (11) :10631-10647.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
PLK4

Related Products

CatalogName
HY-170799HNC-1664
HY-101939RP-001
HY-116260RP-69758
HY-100530ARp-cAMPS
HY-P11107-01RP-832c
HY-100481RP 72540
HY-10015348740 RP
HY-108483-01RP 67580
HY-16437-01RP-64477
HY-158346RP-2119

Alternative Products

CatalogName
BUP22364-01RP-1664
256740-01SR 1664
T205157-01HNC-1664
BLG-C118-005Rp, Rp-c-diAMPSS
BLG-C129-005Rp, Rp-c-diGMPSS
33-610Gamma Catenin Antibody [CTNG/1664]
M10967-01RP-5063
MBS3845539-01RP-64477
MBS3615197-01RP 48497
MBS387143-01RP 54275

Popular Products